Grant: Travel Awards - Institute Community Support

Ovarian cancer is the most common gynecological cancer and is the fifth most common cause of cancer-related death in women. Approximately 70% of ovarian cancers are known as high-grade serous ovarian cancers (HGSOCs), which are characterized by rapid growth rates and spreading within the abdominal cavity. While HGSOCs initially respond to treatment, drug resistance is a common problem leading to disease recurrence and contributing to poor patient outcomes. I am investigating two genes (SKP1 and CUL1) suspected to be involved in the early stages of ovarian cancer development as well as in drug resistance. Using a variety of genetic, biochemical, and imaging techniques, I seek to characterize the effects of altered SKP1 and CUL1 at the molecular level and how this may give rise to ovarian cancer. My research will improve our understanding of the early events that cause normal cells to become cancerous, which is critical for cancer prevention and/or earlier detection. Additionally, my work will provide insights into the driving forces behind tumor evolution and the emergence of drug resistance, which will enable subsequent studies aimed at developing novel therapeutic strategies to improve outcomes for those living with HGSOC.